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Intermediate-term outcome of carotid
endarterectomy with bovine pericardial patch closure
compared with Dacron patch and primary closure
Karen J. Ho, MD, Louis L. Nguyen, MD, MBA, MPH, and Matthew T. Menard, MD, Boston, Mass
Objective: Multiple studies have established that patch angioplasty following carotid endarterectomy (CEA) reduces the
risk of subsequent stroke and restenosis compared with primary closure. Previous reports have also demonstrated bovine
pericardium to be associated with similar rates of postoperative complications and restenosis compared with other patch
materials. Due to favorable handling and sonographic properties, bovine pericardium has become increasingly popular as
a patch option in recent years. However, the intermediate- and long-term performance of this material remains
incompletely defined. Through a retrospective analysis of our carotid endarterectomy experience, we sought to compare
the bleeding, infection, and pseudoaneurysm rates with bovine pericardium patch closure to those with Dacron patch and
primary closure. In this study, 1331 primary carotid endarterectomies performed in our institution between 1996 and
2008 were grouped according to the method of arteriotomy closure: primary closure (PC) (216, 16.3%), Dacron patch
angioplasty (DPA) (642, 48.2%), and bovine pericardial patch angioplasty (BPA) (457, 34.3%). Demographic variable
and postoperative outcome measures collected real-time via a designated database manager were assessed by univariate
and multivariate analysis.
Results:Mean follow-up for the entire cohort was 46.1 months. There were no statistically significant differences in rates
of postoperative wound infection, hematoma, pseudoaneurysm formation, or 30-day stroke or 30-day mortality among
the three groups. Combined 30-day stroke and death was significantly lower in the PC cohort (0.5% vs 2.3% DPA vs 2.4%
BPA; P .94, BPA vs DPA; P .001, BPA vs PC; P .001, DPA vs PC), while 5-year restenosis after both DPA (2.0%
0.6%) and BPA (1.1% 0.6%) was significantly lower compared with PC (5.2% 1.6%) (P .03, DPA vs PC; P .008,
BPA vs PC; P  .14, BPA vs DPA). Five-year survival following BPA (77.9%  3.6%) was significantly improved
compared with PC (66.9%  3.5%) and DPA (60.8%  2.1%) in univariate analysis (P  .24, DPA vs PC; P  .01, BPA
vs PC; P .03, BPA vs DPA), with statin use (P .004) and male gender (P .05) being positive predictors of enhanced
survival on multivariate analysis.
Conclusions: This single-institution, retrospective review represents the largest reported experience with BPA after CEA
to date and is the only report comparing outcomes after BPA to PC or to DPA. Our experience further demonstrates that
patch angioplasty is protective against restenosis after CEA compared with PC. Equivalent rates of perioperative
bleeding, infection, and pseudoaneurysm formation were seen with each closure strategy in this study. (J Vasc Surg
2012;55:708-14.)
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eThe gold standard treatment of critical internal carotid
artery stenosis remains carotid endarterectomy (CEA),
which has been shown in multiple studies to reduce the risk
of stroke and death in patients with both symptomatic and
asymptomatic lesions.1-4 Autologous saphenous vein patch
closure after CEAwas described as early as 1962.5 Based on
an extensive literature accumulated subsequently, patch
angioplasty closure has become the standard of care given
its proven association with lower rates of recurrent carotid
stenosis and stroke.6-9
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708A variety of carotid patches have been utilized over
ime. While saphenous vein offers excellent results, the
eed for a second incision and the occasional experience
ith catastrophic patch blowout with distal saphenous
ein10,11 spurred periods of experimentation with jugular
nd cervical veins and cryopreserved saphenous vein as
lternative options. Prosthetic patches offer the consider-
ble advantage of being readily available, though they carry
he risk of enhanced thrombogenicity and increased infec-
ion and bleeding complications compared with autoge-
ous tissue. Dacron and polytetrafluoroethylene (PTFE)
re the most commonly used prosthetic patches12,13; Da-
ron remains in wider use currently given the prolonged
uture line bleeding associated with PTFE.14
Biasi et al15 first reported the use of bovine pericardium
or carotid patch angioplasty in 1996. Due in part to a
erception that it is more resistant to infection than pros-
hetic material, bovine pericardium has also increasingly
een used for patch angioplasty in other vascular beds.16-19
roponents of bovine pericardium have highlighted its
xcellent handling characteristics,20,21 relative compliance,
ow thrombogenicity, and minimal associated suture line
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Volume 55, Number 3 Ho et al 709bleeding.21 Several reports have documented low rates of
infection, pseudoaneurysm, and other complications with
its use,22,23 and acceptable associated postoperative mor-
tality and morbidity.22-25 Concerns over contraction of
bovine spongiform encephalopathy from use of bovine
pericardium have to date proven unfounded.9
We began using bovine pericardial patches on a trial
basis at our institution when the price became comparable
to that of Dacron and have used it almost exclusively since
2003 (Fig 1). We were particularly attracted by the ease of
insonation through the patch and have recently shown that
routine completion duplex following CEA has significantly
lowered our rate of carotid restenosis.26 The literature
comparing bovine pericardial patches with other patch
material or primary closure remains quite limited, how-
ever,21,24,25,27 and the long-term stability and durability of
bovine pericardium patches has yet to be firmly established.
We were particularly interested in assessing the comparative
rates of infection, bleeding, and pseudoaneurysm forma-
tion when bovine pericardial patch angioplasty was com-
pared with other arteriotomy closure strategies. Herein, we
present our short- and intermediate-term outcomes using
bovine pericardium in over 450 patients over 12 years,
which represents the largest published experience to date.
METHODS
In this study, 1331 primary carotid endarterectomies
performed in a continuous fashion at the Brigham and
Women’s Hospital between January 1, 1996 and Decem-
ber 31, 2008 were entered prospectively real-time into a
long-standing registry. Procedures were divided into 3
groups depending on the method of closure of the arteri-
otomy after endarterectomy: primary closure of the carotid
arteriotomy (PC), Dacron patch angioplasty (DPA), and
0.0
20.0
40.0
60.0
80.0
100.0
120.0
1996 1997 1998 1999 2000
BPA
DPA
PC
Pe
rc
en
t c
ar
ot
id
 
en
da
rte
re
ct
om
y
o
pe
ra
tio
ns
Fig 1. Institutional distribution of carotid endarterect
pericardial patch angioplasty; DPA, Dacron patch angiobovine pericardial patch angioplasty (BPA). All procedures were carried out under general anesthesia by attending
ascular surgeons in standard fashion; no eversion endar-
erectomies were performed. Carotid shunting was per-
ormed on a selective basis based on preoperative clinical
tatus and intraoperative electroencephalogram monitor-
ng findings. Demographic factors and comorbid condi-
ions in the entire cohort and in each group were recorded and
valuated. Renal failure was defined as dialysis-dependence, his-
ory of renal transplant, or serum creatinine2.0mg/dL. Cor-
nary artery disease (CAD) was defined as a history of
yocardial infarction, angina, coronary artery bypass graft-
ng prior to CEA, or preoperative documentation of CAD
y a cardiologist. For patients who underwent CEA with
PA, a processed bovine pericardial patch (either Vascu-
uard; Synnovis Surgical Innovations, St. Paul, Minn [cost
131] or No-React; Shelhigh, Union, NJ prior to a Food
nd Drug Administration [FDA] recall request in 2007)
as used. The patch was rinsed in sterile saline solution
ccording to the manufacturer’s instructions prior to use.
he Dacron patch used almost exclusively was the He-
ashield Platinum Finesse (Maquet, Inc, Wayne, NJ [cost
91]). Patch repair was typically performed using two
trands of 6-0 prolene suture in a running fashion. It has
een our practice since 2000 to perform intraoperative
ompletion duplex following patch closure to assess for
echnical problems.26 Standard antiplatelet therapy was
outinely used following carotid endarterectomy, and sur-
eillance carotid duplex was typically performed 1 month
ostoperatively and yearly thereafter to assess for carotid
estenosis. Endpoints of perioperative infection, neck he-
atoma, pseudoaneurysm, 30-day stroke, 30-day mortal-
ty, combined 30-day stroke and death, 5-year restenosis,
nd 5-year survival were assessed. Infection was defined as a
ositive neck wound culture or need for intravenous anti-
iotics or neck exploration for infection. A neck hematoma
2002 2003 2004 2005 2006 2007 2008
arteriotomy closure method over time. BPA, Bovine
; PC, primary closure.2001
omyas defined as a clinically significant fluid collection visual-
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believed by the reporting attending physician to be consis-
tent with a hematoma, or reoperation for evacuation of
hematoma. All pseudoaneurysms were diagnosed by ultra-
sound or CT at the time of reoperation. A postoperative
stroke was defined as any major neurologic deficit sup-
ported by a confirmatory attending physician note and/or
head CT. Restenosis was defined as the presence of signif-
icant restenosis (75% stenosis at the endarterectomy site
on an imaging study with a confirmatory attending surgeon
note) or occlusion (documented on an imaging study or at
the time of reoperation for thrombectomy). In our vascular
laboratory, a peak systolic velocity 325 cm/s or an inter-
nal carotid artery:common carotid artery ratio of 4:1 cor-
Table I. Patient characteristics and indications for CEA
Entire cohort
n  1331
PC
n  216 (16.3%)
Mean age 70  6.8 72.1  8.1
Male gender 786 (59%) 137 (63.4%)
African American 19 (1.4%) 4 (1.8%)
Diabetes mellitus 554 (26.6%) 51 (23.6%)
Smoking 297 (22.3%) 36 (16.7%)
Hypertension 980 (73.6%) 156 (72.2%)
CAD 627 (47.1%) 123 (56.9%)
COPD 117 (8.8%) 17 (7.9%)
Renal failure 41 (3.1%) 6 (2.8%)
Arrhythmia 10 (7.7%) 11 (5.1%)
Asymptomatic 780 (58.6%) 125 (57.9%)
TIA 256 (19.3%) 45 (20.8%)
Amaurosis fugax 160 (12.0%) 26 (12%)
Recent stroke 135 (10.1%) 20 (9.3%)
BPA, Bovine pericardial patch angioplasty;CAD, coronary artery disease;CO
primary closure; TIA, transient ischemic attack.responds to 75% stenosis.28 tContinuous variables are expressed as mean  stan-
ard deviation. Five-year survival and patency rates were
alculated with the life-table method and compared us-
ng the log-rank life-test. Dichotomous variables were
ompared using 2 analysis and continuous variables
ere compared using the Student t test. Multivariate
nalysis was performed using the Cox proportional haz-
rd model with stepwise backwards elimination. As most
rocedures using DPA were performed prior to 2002
nd most procedures using BPA were performed after
002, we also analyzed the effect of treatment date
oth as a dichotomous and continuous variable in our
ox proportional hazard models. In all comparisons, a
value of .05 was considered the threshold for statis-
DPA
642 (48.2%)
BPA
n  457 (34.3%) P value
68.9  9.3 69.4  9.4 .001 (BPA vs PC)
.41 (BPA vs DPA)
.001 (DPA vs PC)
66 (57%) 273 (59.7%) .36 (BPA vs PC)
.37 (BPA vs DPA)
.098 (DPA vs PC)
10 (1.6%) 5 (1.1%) .42 (BPA vs PC)
.514 (BPA vs DPA)
.77 (DPA vs PC)
61 (25.1%) 138 (30.2%) .08 (BPA vs PC)
.06 (BPA vs DPA)
.67 (DPA vs PC)
52 (23.7%) 105 (23%) .06 (BPA vs PC)
.79 (BPA vs DPA)
.03 (DPA vs PC)
39 (68.4%) 376 (82.3%) .003 (BPA vs PC)
.001 (BPA vs DPA)
.29 (DPA vs PC)
06 (47.7%) 190 (41.6%) .001 (BPA vs PC)
.05 (BPA vs DPA)
.02 (DPA vs PC)
58 (9.0%) 37 (8.1%) .92 (BPA vs PC)
.59 (BPA vs DPA)
.60 (DPA vs PC)
16 (2.5%) 19 (4.2%) .23 (BPA vs PC)
.12 (BPA vs DPA)
.88 (DPA vs PC)
43 (6.7%) 45 (9.8%) .04 (BPA vs PC)
.06 (BPA vs DPA)
.40 (DPA vs PC)
54 (55.1%) 292 (63.9%) .13 (BPA vs PC)
.004 (BPA vs DPA)
.49 (DPA vs PC)
35 (21%) 73 (16%) .12 (BPA vs PC)
.04 (BPA vs DPA)
.95 (DPA vs PC)
83 (13%) 48 (10.5%) .55 (BPA vs PC)
.22 (BPA vs DPA)
.74 (DPA vs PC)
70 (10.9%) 44 (9.6%) .88 (BPA vs PC)
.49 (BPA vs DPA)
.50 (DPA vs PC)
hronic obstructive pulmonary disease;DPA,Dacron patch angioplasty; PC,n 
3
1
1
4
3
3
1
PD, cical significance.
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Demographic and comorbid variables for the entire
cohort and defined subgroups are listed in Table I. Primary
arteriotomy closure was performed in 216 cases (16.3%),
DPA in 642 cases (48.2%), and BPA in 457 cases (34.3%).
The graphic depiction of our adoption of bovine pericar-
dium as a patch material over time is represented in Fig 1.
Patients undergoing BPA were more likely to be hyperten-
sive and asymptomatic at the time of CEA compared with
those undergoing DPA, while patients who underwent PC
were slightly older, more likely to have CAD, and less likely
to smoke. Rates of intraoperative completion duplex were
19%, 48%, and 95% in the PC, DPA, and BPA groups, while
rates of intraoperative completion angiography in the three
groups were 67%, 43%, and 4%. Yearly duplex surveill-
ance was available for 57% of those in the PC group, 64% in
the DPA group, and 79% of the BPA group. Mean follow-
up time for the entire cohort was 46.1  40.2 months
(median 38.2, range 0-181.7 months). Subgroup mean
follow-up times were PC, 46.1 48.2months (median 38.2,
range 0-181.7 months); DPA, 57.3 42.2 months (median
Table II. Outcomes after CEA in entire cohort and accor
Entire cohort
n  1331
PC
n  216 (16.3%
Infection 5 (0.3%) 0
Neck hematoma 42 (3.2%) 5 (2.3%)
Pseudoaneurysm 3 (0.2%) 0
30-day stroke 21 (1.6%) 1 (0.5%)
30-day death 11 (0.8%) 0
Combined 30-day stroke
and death
27 (2%) 1 (0.5%)
BPA, Bovine pericardial patch angioplasty; DPA, Dacron patch angioplasty
Table III. Restenosis and survival at 5 years
Entire cohort
n  1331
PC
n  216 (16.3%)
5-year restenosis 9.1  0.4 5.2  1.6
5-year survival 70.8  1.6 86.9  3.5
BPA, Bovine pericardial patch angioplasty; DPA, Dacron patch angioplasty
All data shown as percent  SD.52.4, range 0-165.6 months); BPA, 24.6  21.2 months tmedian 19.6, range 0-113.0 months). Seven percent of the
PA cohort, 29% of the DPA cohort, and 16% of the PC
ohort were lost to follow-up. As shown in Table II, the
verall rates of postoperative infection, neck hematoma, and
seudoaneurysm formationwere low across each closure strat-
gy. While there were no significant differences in either the
ates of these complications or in 30-day stroke or 30-day
eath, the combined 30-day stroke and death rate was signif-
cantly lower in the PC cohort. Combined 30-day stroke and
eath was significantly lower in the PC cohort (0.5% vs 2.3%
PA vs 2.4% BPA; P .94, BPA vs DPA; P .001, BPA vs
C; P  .001, DPA vs PC). Patching was associated with
mproved 5-year restenosis compared with PC (Table III, Fig
) and a trend toward improved results with bovine pericar-
ium vs Dacron was noted. None of the variables tested on
nivariate analysis proved significant predictors of restenosis
Table IV).
Five-year survival was significantly higher in patients
ho underwent BPA compared with those who underwent
PA or PC (see Table III, Fig 3). Given that 95% of CEAs
rom 2003 onward were performed with BPA, we analyzed
to type of arteriotomy closure
DPA
n  642 (48.2%)
BPA
n  457 (34.3%) P value
2 (0.3%) 3 (0.6%) .23 (BPA vs PC)
.73 (BPA vs DPA)
.41 (DPA vs PC)
21 (3.3%) 13 (3.5%) .41 (BPA vs PC)
.84 (BPA vs DPA)
.48 (DPA vs PC)
2 (0.3%) 1 (0.2%) .49 (BPA vs PC)
.77 (BPA vs DPA)
.41 (DPA vs PC)
14 (2.2%) 6 (1.3%) .31 (BPA vs PC)
.29 (BPA vs DPA)
.096 (DPA vs PC)
5 (0.8%) 6 (1.3%) .38 (BPA vs DPA)
.09 (BPA vs PC)
.19 (DPA vs PC)
15 (2.3%) 11 (2.4%) .94 (BPA vs DPA)
.001 (BPA vs PC)
.001 (DPA vs PC)
rimary closure.
DPA
642 (48.2%)
BPA
n  457 (34.3%) P value
2.0  0.6 1.1  0.6 .03 (DPA vs PC)
.008 (BPA vs PC)
.15 (BPA vs DPA)
9.8  2.1 77.9  3.6 .24 (DPA vs PC)
.01 (BPA vs PC)
.03 (BPA vs DPA)
rimary closure.ding
)n 
6he effect of treatment date and found no statistical evi-
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March 2012712 Ho et aldence to suggest that temporal bias was a contributing
factor in the observed enhanced survival seen. Similarly, to
determine if improved cardiovascular risk management
with antiplatelet agents, -blockers and statin therapy in-
fluenced survival in the BPA cohort, we included the peri-
operative use of these medications in our regression analy-
sis, the results of which are in Table IV. While patients in
the BPA cohort were more likely to be on statin and dual
aspirin and Plavix antiplatelet therapy and less likely to be
on Coumadin than those in either the DPA or PC sub-
5-year re
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Fig 2. Five-year cumulative restenosis (with numbers
Dacron patch angioplasty; PC, primary closure.
Table IV. Multivariate analysis of 5-year restenosis and
survival
Variable
5-year restenosis 5-year survival
P value Hazard ratio P value
Age .15 .95 .001
Prior stroke .12 .83 .001
Renal failure 1.0 .29 .001
Statina .74 1.3 .004
Arrhythmia 1.0 .71 .004
Male gender .55 1.21 .05
Diabetes mellitus .73 .77 .02
COPD .72 .67 .02
CAD .10 .91
Hypertension .10 .76
Plavixa .45 .60
Dacron patch .06 .43
Beta blockera .59 .39
Smoking .49 .36
Aspirina .39 .34
Bovine patch .15 .21
Indication for CEA .28 .18
Coumadina .94 .11
CAD, Coronary artery disease; CEA, carotid endarterectomy; COPD,
chronic obstructive pulmonary disease.
aPostoperative.groups (Table V), only statin therapy proved to be a signif- icant predictor of enhanced survival on multivariate analy-
is. Male gender also positively predicted survival, while
dvanced age, diabetes mellitus, prior stroke, chronic ob-
tructive pulmonary disease, renal failure, and the presence
f an arrhythmia negatively influenced survival onmultivar-
ate analysis.
ISCUSSION
At our institution, PC of the arteriotomy during CEA
as routinely practiced until 1997. Between 1997 and
003, closure with DPA became the more commonly
erformed technique, with 75% of procedures being per-
ormed in this manner and 25% being closed primarily.
rom 2003 onward, 95% of all CEAs have been performed
tilizing bovine pericardium. We have been swayed toward
se of this patch material by its ready availability, excellent
andling characteristics, minimal associated suture hole
leeding, comparative cost, relative resistance to thrombo-
is, and the ability to insonate directly through the patch.
e believe this latter feature confers a clear advantage over
rosthetic alternatives and has allowed us to significantly
educe our restenosis rates below those commonly re-
orted.26 Concerns over immunogenicity or infection with
ovine spongiform encephalopathy do not appear to be
linically relevant given current preparation techniques.9
hile several reports have indicated that bovine pericar-
ium can be used effectively as a carotid patch,15,20-25 there
re few comparative studies between bovine pericardium
nd Dacron patches, and the longer-term risk of associated
atch infection or patch degeneration with bovine pericar-
ium remains unclear.
The most notable finding in our study was that of the
omparatively low rates of postoperative infection and
leeding across each closure strategy, again demonstrating
he short-term safety of using bovine pericardium for this
nosis
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Volume 55, Number 3 Ho et al 713indicated by a higher pseudoaneurysm rate were not real-
ized across the intermediate follow-up period represented
by this series.
We do not have a ready explanation for the unexpected
finding of improved 30-day stroke and death rates with PC
in our study. This result represents an exceptionally low
stroke and death rate for both symptomatic and asymptom-
atic patients in the PC cohort and runs counter to the
wealth of accumulated data from multiple randomized
controlled trials indicating improved perioperative stroke
and death with patching. Consistent with an abundance of
prior literature,6,7 however, our study found improved
long-term patency with both types of patches compared
with PC of the arteriotomy. The observed trend toward
improved patency favoring bovine pericardium over Da-
cron could potentially be explained by our adoption of
completion duplex as a standard practice beginning shortly
after transitioning to bovine pericardium as our patch of
choice.26
Predictors of long-term survival in the entire cohort
were similar to those well known to affect mortality in this
patient population. However, the enhanced survival seen
with bovine patch angioplasty on univariate analysis was an
unexpected result, and we remain cautious with regard to
drawing any strong conclusions from this finding. While it
potentially reflects the now widely known beneficial effects
of statin therapy in patients with cardiovascular dis-
5-yea
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Fig 3. Five-year cumulative survival (with numbers at ri
patch angioplasty; PC, primary closure.
Table V. Selected cardiovascular medications used periope
Medication DPA vs PC (P value)
Beta blocker 61% vs 57% (.34)
Statin 49% vs 44% (.22)
Aspirin and Plavix 3% vs 3% (.64)
Coumadin 3% vs 6% (.03)
BPA, Bovine pericardial patch angioplasty; DPA, Dacron patch angioplastyease,31,32 it could also reflect a temporal bias undetected by Wur statistical efforts; we acknowledge the challenges in
ompletely eliminating such bias in retrospective studies
uch as ours.
The discrepant rate of asymptomatic patients, age, and
egree of coronary disease in the BPA cohort is a further
ecognized limitation of the study and could also bear on
he identified survival advantage. Additional limitations
nclude the inherent subjectivity of our definition of neck
ematoma and the lack of information on internal carotid
rtery diameters in those patients undergoing PC. Finally,
hile the survival analysis methods used in this study
hould control for the variability in follow-up seen in the
ifferent subgroups and account for the uncertainty of
ensorship, we recognize the inherent limitations of the
tatistical analysis.
In sum, our findings support the use of bovine pericar-
ium as a patch material after carotid endarterectomy and
uggest it is safe in the short and intermediate-term for this
ndication.
The authors thank Ms Julie Lombara for her assistance
n data management.
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